| Registry | NCT03209063 |
|---|---|
| Status | Unknown |
| Study type | Observational |
| Enrollment | 285 (Estimated) |
| Sponsor | Assiut University (Other) |
| Conditions | Recurrent Miscarriage |
| Interventions | polymerase chain reaction (Diagnostic test) |
| Dates | start 2022-07-01 (estimated), primary completion 2022-08-01 (estimated), completion 2022-09-30 (estimated), first posted 2017-07-06, last updated 2022-06-30 |
Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Recurrent Miscarriage All trials of polymerase chain reaction
Recurrent miscarriage is a pregnancy loss before 20 weeks of gestation. The recurrent pregnancy loss(RPL) usually occurring in the first trimester of gestation and its rate is quite high (15-20% even in full reproductive period) . In 2012, the American Society for Reproductive Medicine Practice Committee issued a statement that defined recurrent pregnancy loss as a disease distinct from infertility defined by two or more failed consecutive pregnancies.approximately 40% of couples will have an etiology identified that could be associated with their loss.
Recurrent miscarriage is a pregnancy loss before 20 weeks of gestation. The recurrent pregnancy loss usually occurring in the first trimester of gestation and its rate is quite high (15-20% even in full reproductive period) . In 2012, the American Society for Reproductive Medicine Practice Committee issued a statement that defined recurrent pregnancy loss as a disease distinct from infertility defined by two or more failed consecutive pregnancies.approximately 40% of couples will have an etiology identified that could be associated with their loss.Thrombophilia is the tendency to develop thromboses due to inherited defects in the coagulation system.Thrombophilia was identified as a major cause of RPL,Because pregnancy is a hypercoagulable state, thromboembolism is the leading cause of antepartum and postpartum maternal mortality .The four most common genetic markers for thrombophilia are; prothrombin gene mutation(FII, G20210A), methylene tetra hydrofolate reductase mutations (MTHFR ,C677T and A1298C), factor V Leiden (FVL, G1691A) , and plasminogen activator inhibitor 1 (PAI-1) . Prothrombin G20210A refers to a human gene mutation that increases the risk of blood clots . Approximately 1 in 50 people in the white population in the United States and Europe has prothrombin thrombophilia. Study was conducted to evaluate the frequency of PT20210 among healthy Egyptians, (1.06%) had PT20210 G-A mutation.The variant causes elevated plasma prothrombin levels (hyperprothrombinemia), Prothrombin is the precursor to thrombin, which plays a key role in causing blood to clot (blood coagulation).Prothrombin G20210A can thus contribute to a state of hypercoagulability . Methylene tetra hydrofolate reductase (MTHFR) is the rate-limiting enzyme in the methyl cycle, and it is encoded by the Methylene tetra hydrofolate reductase gene. It was thought that deficient Methylene tetra hydrofolate reductase, by causing elevated homocysteine levels, led to an increased risk of venous thrombosis, coronary heart disease, and recurrent pregnancy loss . Previous studies suggested that percentage of PT20210 in patients with unexplained RPL is ( 10.9%),however searching literatures didn't find any estimation of this percentage in Egyptian population.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Group I | Diagnostic Test: polymerase chain reaction | 195 Patients having history of two or more miscarriages. | |
| Group II | Diagnostic Test: polymerase chain reaction | 90 healthy controls less than 35 years with no history of miscarriage and at least one uncomplicated full-term pregnancy |
Sex: Female, ages: 17 Years to 35 Years, accepts healthy volunteers
Inclusion Criteria 1. Age less than 35 years. 2. History of two or more spontaneous miscarriages Exclusion Criteria: 1. Age more than 35 years. 2. . Women with elevated level of TSH above (2.5 mIU/ml) and uncontrolled DM. 3. Women with autoimmune disorder (antiphospholipid antibody syndrome)with LA1/LA2 ratio more than( 1.2). 4. Women receiving oral contraceptive pills and anticoagulant drugs.